Skip to content

Trial of Family Focused Grief Therapy in Palliative Care and Bereavement

Randomized Controlled Trial of Family Focused Grief Therapy in Palliative Care and Bereavement

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00580515
Enrollment
700
Registered
2007-12-24
Start date
2005-11-08
Completion date
2026-03-11
Last updated
2026-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

Cancer, Randomized Controlled Trial, Family Therapy intervention

Brief summary

The purpose of this study is to learn how well family therapy works if given while a family member is being treated for a serious illness and whether it helps their family to continue meeting for a time after their death. The therapy aims to assist the family communication and support during both palliative care and bereavement. The investigators also want to learn how many family therapy sessions spread out over time are best for helping patients and their families. Patients are randomly assigned to one of three groups: patients who receive standard palliative care, patients and their families who take part in 6 sessions, and patients and their families who take part in 10 sessions.

Detailed description

This Randomized Controlled Trial (RCT) seeks to test the efficacy and dose responsiveness of a manualized family therapy intervention called Family Focused Grief Therapy (FFGT), which is delivered to families of patients with advanced disease and continued into bereavement. Randomization is to three arms: 6 sessions of FFGT, 10 sessions of FFGT, or standard care. The study also explores the potential mediators of effective outcome, empowering further refinement of the intervention, and undertakes an analysis of health-related costs of bereavement care. It is a multi-site study involving Memorial Hospital for Cancer and Allied Diseases (a comprehensive cancer center), Calvary Hospital (a dedicated palliative care hospital with home hospice care program)and Beth Israel (a medical center with a dedicated pain and palliative care department. Consenting families will be assessed at baseline through completion of questionnaires that appraise each individual's psychosocial well-being and perception of their family's functioning. Therapy will be delivered by family therapists (social workers, psychologists, and psychiatrists), who will attend regular supervision sessions to sustain fidelity of the model of intervention. Follow-up of family members for psychosocial well-being, perceptions of family functioning, and costs of heath-related care will occur at 3, 6, 9, & 13 months after the patient's death or completion of therapy sessions.

Interventions

BEHAVIORALFamily Focused Group Therapy

6 Sessions of Family Focused Group Therapy (FFGT). The FFGT intervention will have assessment, focused therapy, consolidation, and termination phases. The first two sessions are assessment sessions and occur one week apart. There will be two or six focused intervention sessions depending on the predetermined length of therapy. The first focused intervention session is approximately two weeks after the last assessment session. Subsequent focused intervention sessions are expected to follow once every month. Finally, there will be two consolidation/termination sessions, which will occur one time each, approximately two months apart. The six session program is expected to extend over a period of 6 months and the 10 session program over 10 months.

BEHAVIORALStandard of Care

Standard of Care Families assigned to the Usual Care Condition will receive standard psychosocial care which is based on the following patterns: Social work consultations are routinely provided to the cancer patients, but relatives are only seen during admissions or upon request.

Sponsors

Memorial Sloan Kettering Cancer Center
Lead SponsorOTHER
National Cancer Institute (NCI)
CollaboratorNIH
Beth Israel Medical Center
CollaboratorOTHER
Calvary Hospital, Bronx, NY
CollaboratorOTHER
Monash University
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Subject/Patient Inclusion Criteria * Individuals with advanced disease/Stage 4-IV cancer who may be involved in palliative care treatment program. * Individuals with a poor prognosis Patient and Family Member Inclusion Criteria. * Per investigator's judgment participants must have satisfactory cognitive functioning to provide valid informed consent and participate in family therapy. * In the event that the index family member is declining or too frail to take part in family meetings, the family is able to participate without the index patient being involved in the study. * For every enrolled family there must be at least 2 family members willing/able to take part at the time of recruitment. * The presence of FRI screening scores of ≤ 9 or cohesiveness subscale score \< 4 based on the perception of any single family member, including the patient.

Exclusion criteria

* Inability through language to complete the study questionnaires - inability to speak English with an English-speaking therapist. * Age less than 12 years old for a child. * Patient and family member determined geographical inaccessibility to attend family sessions. * Significant psychiatric disturbance sufficient, in the investigator's judgment, to preclude participation in a psychotherapeutic intervention.

Design outcomes

Primary

MeasureTime frame
Evaluate the efficacy and dose responsiveness of family intervention in preventing bereavement and depression compared with standard palliative care among family members and to examine whether distress moderates impact of FFGT5 years

Secondary

MeasureTime frame
Evaluate whether family coping and communication mediate the impact of FFGT and examine costs of FFGT and standard palliative care, and whether the additional costs are offset by reductions in community health utilization5 years

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORTalia Zaider, PhD

Memorial Sloan Kettering Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 14, 2026